2m 2m 2m 2m 2m 2m 2m
DAMORA THERAP (DMRA)
NASDAQ
$21.68-$0.04 (-0.16%)
Price as of Oct 22, 2026 7:30 PM EDT- $1.9BMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
DAMORA THERAP (DMRA)
$21.68-$0.04 (-0.16%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.2M +38.27% | 844,000 -50.03% | 1.7M +133.93% | 722,000 +362.82% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 1.2M +38.27% | 844,000 -50.03% | 1.7M +133.93% | 722,000 +362.82% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -26.9M +320.08% | -6.4M -73.08% | -23.8M -50.69% | -48.2M +25.25% | |
Depreciation and Amortization Expense | 22,000 +4.76% | 21,000 -92.19% | 269,000 +540.48% | 42,000 +110.00% | |
Total Operating Expenses | 210.9M +847.31% | 22.3M -44.22% | 39.9M -34.80% | 61.2M +17.19% | |
Operating Profit | -210.9M +847.31% | -22.3M -44.22% | -39.9M -34.80% | -61.2M +17.19% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 1.1M +25.64% | 862,000 -44.60% | 1.6M +473.14% | -417,000 -187.79% | |
Income before Taxes | -209.8M +880.41% | -21.4M -46.38% | -39.9M -34.80% | -61.2M +17.19% | |
Income Taxes | 50,000 +21.95% | 41,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -209.8M +878.77% | -21.4M -44.10% | -38.3M -37.77% | -61.6M +19.08% | |
Net Income from Continuing Operations Applicable to Common | -209.8M +880.41% | -21.4M -44.20% | -38.3M -37.77% | -61.6M +19.08% | |
Basic EPS and Net Income | -23,816.00 +128,426.71% | -18.53 +1,186.81% | -1.44 -40.74% | -2.43 +18.54% | |
Diluted EPS and Net Income | -23,816.00 +128,426.71% | -18.53 +1,186.81% | -1.44 -40.74% | -2.43 +18.54% | |
Basic Weighted Average Shares | 2,332 -99.80% | 1.2M -95.65% | 26.6M +4.58% | 25.4M +0.58% | |
Diluted Weighted Average Shares | 2,332 -99.80% | 1.2M -95.65% | 26.6M +4.58% | 25.4M +0.58% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 257.6M +1,717.45% | 14.2M -33.96% | 21.5M -34.53% | 32.8M -47.60% | |
Short-Term Investments | N/A N/A | 11.7M 0.00% | 11.7M -57.41% | 27.4M -27.08% | |
Cash and Cash Equivalents and Short-Term Investments | 257.6M +896.19% | 25.9M -21.99% | 33.2M -44.95% | 60.2M -39.89% | |
Total Current Assets | 260.4M +1,446.55% | 16.8M -54.21% | 36.8M -42.46% | 63.9M -41.95% | |
Accumulated Depreciation | 72,000 +44.00% | 50,000 +72.41% | 29,000 -53.23% | 62,000 +210.00% | |
Property and Plant and Equipment and Net | 36,000 -36.84% | 57,000 -26.92% | 78,000 -78.15% | 357,000 +75.86% | |
Total Long-Term Assets | 0 -100.00% | 163,000 -85.55% | 1.1M -50.50% | 2.3M +12.38% | |
Total Assets | 260.5M +1,420.70% | 17.1M -55.18% | 38.2M -47.77% | 73.2M -40.12% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 20.1M +1,576.36% | 1.2M -79.47% | 5.8M -47.51% | 11.1M +144.43% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 28,000 -34.88% | 43,000 -34.85% | 66,000 -79.88% | 328,000 -26.79% | |
Total Liabilities | 20.1M +1,448.58% | 1.3M -77.93% | 5.9M -48.44% | 11.4M +129.07% | |
Retained Earnings | -487.4M +75.61% | -277.5M +8.37% | -256.1M +17.61% | -217.7M +39.47% | |
Total Stockholders Equity | 240.4M +1,418.41% | 15.8M -51.03% | 32.3M -47.64% | 61.8M -47.32% | |
Total Shares Outstanding | 1.6M +21.29% | 1.3M -95.14% | 27.1M +5.69% | 25.7M +1.55% | |
Cash Flow | |||||
Cash from Operating Activities | -6.7M -63.88% | -18.6M -49.55% | -36.9M -14.02% | -42.9M -17.92% | |
Capital Expenditures | N/A N/A | N/A N/A | 196,000 0.00% | 196,000 -12.11% | |
Cash from Investing Activities | -17.4M -249.13% | 11.7M -47.83% | 22.3M +80.31% | 12.4M +125.77% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 266.8M +9,178.30% | 2.9M 0.00% | 2.9M +467.26% | 507,000 -99.73% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -18,069.58% +585.12% | -2,637.44% +11.63% | -2,362.64% -72.13% | -8,477.42% -74.68% | |
Return on Assets | -151.15% +95.15% | -77.45% +12.51% | -68.84% +9.14% | -63.07% +79.04% | |
Return on Equity | -163.80% +83.99% | -89.03% +9.21% | -81.52% +18.38% | -68.86% +88.09% | |
Revenue Growth | 38.27% +176.49% | -50.03% -137.35% | 133.93% -63.09% | 362.82% N/A | |
Current Ratio | 12.98 -7.74% | 14.07 +123.02% | 6.31 +9.62% | 5.75 -76.25% | |
Cash Ratio | 12.84 +8.42% | 11.84 +221.64% | 3.68 +24.73% | 2.95 -78.56% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow